Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Oct 22, 2024Closes
Oct 20, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification), For profit organizations other than small businesses, City or township governments, Private institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Small businesses, Special district governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, County governments, Public and State controlled institutions of higher education, State governments
Description
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.